BLS Pharmaceuticals Enters Non-Binding Agreement with Trexapharm to Launch TREXAVIVE® in Australia

Understanding TREXAVIVE® and Its Role in Treatment-Resistant Depression

TREXAVIVE® is a proprietary, patented neurotherapy developed by Trexapharm for treatment-resistant depression, Major Depression Disorder, and trauma-related disorders such as PTSD. It offers a differentiated mental health treatment by combining low doses of flumazenil and naltrexone, designed for administration within existing psychiatric outpatient settings. Unlike some advanced mental health therapies, TREXAVIVE® is non-sedating and does not require sedation, dissociation, or specialised hospital infrastructure.

Early clinical results from a small open-label study involving 10 patients who had failed at least three prior therapies demonstrated encouraging safety, tolerability, and efficacy signals, with symptom improvement observed from Day 4. However, these results are preliminary and require validation through larger controlled clinical trials. The outpatient administration model aligns strategically with BLS's commercial infrastructure and healthcare relationships, making it an ideal fit for the Australian commercialisation partnership.

BLS Pharmaceuticals Expands into Mental Health Neurotherapy

BLS Pharmaceuticals Limited, an Australian company, specialises in manufacturing, developing, and commercialising regulated therapeutic products and active pharmaceutical ingredients. Through its wholly owned subsidiary Breathe Life Sciences, BLS operates a GMP-licensed manufacturing, import, export, and distribution platform covering medicinal cannabis, psychedelic medicines, and other controlled pharmaceuticals. The company serves markets across Australia, Europe, the UK, and Japan via an expanding network of commercial partners.

The TREXAVIVE® collaboration represents a significant extension of BLS's mental health portfolio beyond cannabis-based and psychedelic medicines. Managing Director Sam Watson highlighted that the partnership enables BLS to introduce differentiated, non-sedating treatment options to Australian psychiatrists and patients. This expansion enhances BLS's mental health offerings and showcases the value of its commercial platform and healthcare relationships, positioning the company to seize additional opportunities in the regulated mental health therapeutics market.

Non-Binding Heads of Agreement: Roles and Responsibilities

Under the Heads of Agreement, BLS will become Trexapharm's preferred Australian commercial partner for TREXAVIVE®, leveraging its established connections with psychiatrists, mental health clinics, and healthcare providers to support market introduction. BLS will manage commercialisation efforts, patient access support, and evaluate manufacturing and supply as the program advances. Patient access will be facilitated via the Therapeutic Goods Administration's Special Access Scheme (SAS) Category B and Authorised Prescriber pathways.

Trexapharm retains responsibility for TREXAVIVE®'s clinical development and intellectual property, protected by patents in Australia and the US, along with international applications. This arrangement allows Trexapharm to maintain control over its core IP and clinical strategy while utilising BLS's commercial and manufacturing strengths in Australia. The Heads of Agreement remains non-binding, serving as a framework for negotiating definitive commercial contracts, with further due diligence and negotiations pending.

Exploring Australian Manufacturing and Delivery Systems

The partnership includes plans to investigate Australian manufacturing of TREXAVIVE®, including subcutaneous infusion and nasal spray delivery methods. This offers BLS the opportunity to use its GMP-licensed manufacturing platform to produce and supply the therapy domestically. Considering multiple delivery systems aims to optimise patient experience and clinical outcomes. Developing manufacturing capabilities in Australia could support both local commercialisation and regional supply to nearby markets.

Establishing Australian manufacturing aligns with BLS's strategy as an international pharmaceutical manufacturer and supplier. These manufacturing discussions are preliminary, with scope and scale to be determined as definitive agreements are negotiated. This manufacturing component could generate additional revenue and enhance BLS's position in the regulated pharmaceutical manufacturing sector.

International Growth and Veteran Mental Health Focus

Beyond Australia, the companies plan to explore international markets including the UK, manufacturing and supply arrangements, veteran and defence mental health initiatives, expanded commercial rights, partnerships, and potential strategic investments. The focus on the UK market highlights TREXAVIVE®'s broader potential. Targeting veteran and defence mental health addresses the significant burden of treatment-resistant depression in these populations.

The broad scope of potential collaborations suggests a long-term strategic relationship that may evolve considerably from the current non-binding agreement. The emphasis on veteran and defence mental health reflects sensitivity to these populations' needs and BLS's growing expertise in mental health therapeutics.

Patient Access and Regulatory Strategy in Australia

The collaboration will facilitate patient access to TREXAVIVE® through the Therapeutic Goods Administration's Special Access Scheme (SAS) Category B and Authorised Prescriber pathways. These regulatory routes allow patients who have exhausted conventional treatments to access unapproved therapies. The SAS Category B pathway is especially relevant for innovative medicines targeting serious conditions without alternatives. Leveraging these pathways enables patient access while larger clinical trials continue.

Recognising treatment-resistant depression as a critical unmet need in Australia, Managing Director Sam Watson noted the daily challenges faced by millions and the lack of options after standard therapies fail. Establishing clear patient access pathways demonstrates the partnership's commitment to making TREXAVIVE® available as clinical evidence grows, while building commercial relationships with psychiatrists and mental health clinics.

Trexapharm’s Expertise and Development Approach

Trexapharm Pty Ltd is an Australian biopharmaceutical company focused on science-driven therapies for complex mental health disorders. Its lead product, TREXAVIVE®, is a patented neurotherapy for treatment-resistant depression and trauma-related disorders. Trexapharm’s development strategy leverages repurposed compounds, targeted delivery technologies, and pragmatic regulatory pathways to improve patient access efficiently.

Executive Chairman Lee Rodne stated that Trexapharm sought a commercial partner with strong pharmaceutical manufacturing and commercial capabilities, identifying BLS as an ideal fit. This selection reflects Trexapharm’s recognition that successful therapy development requires both scientific expertise and commercial execution to navigate regulatory and patient access challenges.

BLS’s Leadership in Mental Health Therapeutics and Market Position

BLS Pharmaceuticals is emerging as a leader in regulated mental health therapeutics in Australia, building on its experience with medicinal cannabis and psychedelic medicines. Its subsidiary, Breathe Life Sciences, operates a GMP-licensed manufacturing and distribution platform adept at navigating complex regulatory environments for controlled pharmaceuticals. This expertise, combined with established healthcare relationships and commercial infrastructure, gives BLS competitive advantages as it expands into new mental health treatment categories.

Managing Director Sam Watson views the TREXAVIVE® partnership as validation of BLS’s commercial platform and healthcare networks. Adding TREXAVIVE® enhances BLS’s portfolio, offering psychiatrists and healthcare providers a wider range of differentiated treatments for patients unresponsive to conventional care. This strategy supports BLS’s vision to become an international pharmaceutical manufacturer and supplier across multiple therapeutic areas, with operations spanning Australia, Europe, the UK, and Japan.

Non-Binding Agreement Status and Future Negotiations

The Heads of Agreement between BLS and Trexapharm is explicitly non-binding, serving as a foundation for negotiating definitive commercial agreements. This status means neither party has committed to final commercial or financial terms at this stage. Details regarding financial arrangements, revenue sharing, milestones, or timelines for definitive agreements remain undisclosed, indicating substantial work is needed before operational collaboration begins.

The next critical step involves negotiating and executing binding commercial agreements that will specify commercial terms, financial details, manufacturing responsibilities, intellectual property protections, exclusivity, and dispute resolution. While the parties intend to explore veteran and defence mental health, international expansion, manufacturing, and strategic investments, the extent and likelihood of these progressing to binding agreements are yet to be determined. Investors should monitor updates on negotiation progress and material terms agreed upon.